KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Payables (2019 - 2025)

GoodRx Holdings (GDRX) has disclosed Payables for 7 consecutive years, with $19.4 million as the latest value for Q4 2025.

  • Quarterly Payables rose 37.26% to $19.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19.4 million through Dec 2025, up 37.26% year-over-year, with the annual reading at $19.4 million for FY2025, 37.26% up from the prior year.
  • Payables hit $19.4 million in Q4 2025 for GoodRx Holdings, down from $28.7 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $36.3 million in Q4 2023 to a low of $6.8 million in Q2 2023.
  • Historically, Payables has averaged $19.0 million across 5 years, with a median of $17.1 million in 2021.
  • Biggest five-year swings in Payables: skyrocketed 203.13% in 2023 and later plummeted 62.34% in 2024.
  • Year by year, Payables stood at $17.5 million in 2021, then increased by 1.14% to $17.7 million in 2022, then soared by 104.89% to $36.3 million in 2023, then plummeted by 61.02% to $14.1 million in 2024, then skyrocketed by 37.26% to $19.4 million in 2025.
  • Business Quant data shows Payables for GDRX at $19.4 million in Q4 2025, $28.7 million in Q3 2025, and $25.4 million in Q2 2025.